A Study of MKC-442 in HIV-Positive Patients

Inclusion Criteria Concurrent Medication: Allowed: Based on medical history, medical condition, prior use of antiretroviral drugs, and genotypic analysis of the predominant strain of HIV-1 isolated from plasma, administration of at least 2 available antiviral agents by prescription may be given with MKC-422. Patients must have: \- HIV infection with HIV-1 RNA greater than or equal to 2,000 by Roche Amplicor method, within 30 days of entry. Prior Medication: Allowed: * Prior nucleoside reverse transcriptase and protease inhibitors. * Cytotoxic chemotherapy more than 30 days prior to entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Malabsorption or severe chronic diarrhea within 30 days prior to entry, or inability to consume adequate oral intake because of chronic nausea, emesis, or abdominal or esophageal discomfort. * Inadequately controlled seizure disorder. * Acute and clinically significant medical event within 30 days of screening. * Any clinical or laboratory abnormality greater than Grade 3 toxicity, with the exception of the listed laboratory values. Prior Medication: Excluded: * Non-nucleoside reverse transcriptase inhibitor therapy. * Any unapproved experimental antiretroviral therapy. Prior Treatment: Excluded: * Radiation therapy within 30 days of entry, except to a local lesion. * Transfusion of blood or blood products within 21 days of screening. Risk Behavior: Excluded: Active substance abuse that may interfere with compliance or protocol evaluations.